DALLAS--()--HemoBioTech (Pink Sheets:HMBT) announced today the issuance of a new patent US 7,759,306 B2, “Methods of Treating Acute Blood Loss.” HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026.
“The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.”
The new patent involves HemoTech which induces the production of new red blood cells in the body. Uses for HemoTech could involve the treatment of acute blood loss and anemia in trauma, surgery, cancer, kidney disease and heart disease. The market for treatment of acute anemia is over $2 billion.
HemoTech also has the advantage of delivering oxygen to tissue in the body since it is composed of modified hemoglobin. The combination of delivering oxygen and inducing new red blood cells could be an advantage for treating trauma, elective surgery in third world countries plagued with a high incidence of HIV or Hepatitis contaminated blood and for use by the military and homeland security.
HemoTech is composed of bovine hemoglobin, which is chemically modified with ATP, Adenosine and GSH, to overcome toxicity. HemoTech has been used successfully in an initial clinical study to treat children afflicted with sickle cell anemia, with no apparent side affects. HemoTech stabilizes a cell factor called Hif-1 alpha, which results in induction of erythropoietin, which stimulates an increase in production of new red blood cells.
“HemoTech addresses a multi-billion dollar market for treatment of acute blood loss and anemia with the potential advantage of fewer side affects and the ability to deliver oxygen in acute situations,” said Dr. Arthur P. Bollon, Chief Executive Officer of HemoBioTech. “The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.”
About HemoBioTech, Inc.
HemoBioTech (Pink Sheets:HMBT) is engaged in the commercial development of HemoTech, which addresses the treatment of acute blood loss and acute anemia. HemoTech was developed by Texas Tech University Health Sciences Center scientists, Dr. Mario Feola and Dr. Jan Simoni, and is exclusively licensed by HemoBioTech from Texas Tech University. The composition of HemoTech is based on bovine hemoglobin, which is chemically modified with ATP, Adenosine and GSH.
Researchers have shown that HemoTech carries oxygen in the blood, and induces erythropoiesis (red blood cell production). The Company believes that HemoTech, due to its novel chemical structure, may possess properties that diminish the intrinsic toxicities that have plagued other attempts at developing oxygen carriers, based upon pre-clinical studies and an initial, foreign human clinical study.
HemoTech is being subjected to further studies and testing to confirm and expand on these initial results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, anemia, as well as for treatment of other conditions such as heart disease. HemoTech is an investigational biological drug that has not been approved by the U.S. Food and Drug Administration and cannot currently be marketed.
Contact information is: Arthur P. Bollon, Ph.D. at 972-455-8955 or firstname.lastname@example.org. Corporate headquarters are located at HemoBioTech, Inc., 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244.
HemoBioTech website is www.hemobiotech.com.
Safe Harbor Statement
Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech's Annual Report on Form 10-K for the year ending December 31, 2009 and HemoBioTech's other reports filed with the Securities and Exchange Commission.